Use of glucagon-like peptide-1 (GLP-1) receptor agonists among U.S. children with obesity is increasing rapidly. A national analysis from NYU Langone Health published in Pediatrics found that among children ages 8–11 with obesity and without diabetes, GLP-1 prescribing was 310 times higher in 2026 than it was in 2019 (when the drugs first began reaching the market), with 20,282 children in this age group receiving these medications during the study period. Most treated children had …
Read More